Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)
Condition:   Ulcerative Colitis Interventions:   Drug: AMT-101 (oral);   Other: Placebo (oral);   Combination Product: Humira (adalimumab) Sponsor:   Applied Molecular Transport Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 13, 2022 Category: Research Source Type: clinical trials